Exact Mass: 483.34607400000004
Exact Mass Matches: 483.34607400000004
Found 138 metabolites which its exact mass value is equals to given mass value 483.34607400000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Taurolithocholate
Lithocholyltaurine is a bile salt formed in the liver from lithocholic acid conjugation with taurine, usually as the sodium salt. It solubilizes fats for absorption and is itself absorbed. Lithocholic acid, a hydrophobic secondary bile acid, is well known to cause intrahepatic cholestasis. There have been extensive studies on the mechanisms of lithocholate-induced cholestasis in animals. Lithocholate diminishes both the bile acid-dependent and independent bile flow. In humans, elevated levels of lithocholic acid are found in patients with chronic cholestatic liver disease. Lithocholyltaurine impairs both the bile canalicular contractions and the canalicular bile secretion, possibly by acting directly on the canalicular membranes in lithocholyltaurine-induced cholestasis. Lithocholyltaurine induce acute cholestasis-associated with retrieval of the bile salt export pump. The bile salt export pump (BSEP) of hepatocyte secretes conjugated bile salts across the canalicular membrane in an ATP-dependent manner. Hepatic retention of bile acids may lead to liver injury by hepatocyte apoptosis and eventually deterioration of cholestatic liver diseases. One mechanism of induced apoptosis by lithocholyltaurine is the induction of transcriptional activity of AP-1 (activation protein-1). (PMID: 16981261, 15763547, 16332456, 18164257) [HMDB] Lithocholyltaurine is a bile salt formed in the liver from lithocholic acid conjugation with taurine, usually as the sodium salt. It solubilizes fats for absorption and is itself absorbed. Lithocholic acid, a hydrophobic secondary bile acid, is well known to cause intrahepatic cholestasis. There have been extensive studies on the mechanisms of lithocholate-induced cholestasis in animals. Lithocholate diminishes both the bile acid-dependent and independent bile flow. In humans, elevated levels of lithocholic acid are found in patients with chronic cholestatic liver disease. Lithocholyltaurine impairs both the bile canalicular contractions and the canalicular bile secretion, possibly by acting directly on the canalicular membranes in lithocholyltaurine-induced cholestasis. Lithocholyltaurine induce acute cholestasis-associated with retrieval of the bile salt export pump. The bile salt export pump (BSEP) of hepatocyte secretes conjugated bile salts across the canalicular membrane in an ATP-dependent manner. Hepatic retention of bile acids may lead to liver injury by hepatocyte apoptosis and eventually deterioration of cholestatic liver diseases. One mechanism of induced apoptosis by lithocholyltaurine is the induction of transcriptional activity of AP-1 (activation protein-1). (PMID: 16981261, 15763547, 16332456, 18164257). D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids D013501 - Surface-Active Agents > D003902 - Detergents CONFIDENCE standard compound; INTERNAL_ID 61
Hydroxybuprenorphine
C29H41NO5 (483.29845760000006)
Hydroxybuprenorphine is a metabolite of Buprenorphine. Buprenorphine is a semi-synthetic opioid that is used to treat opioid addiction in higher dosages (>2 mg), to control moderate acute pain in non-opioid-tolerant individuals in lower dosages (~200 µg), and to control moderate chronic pain in dosages ranging from 20–70 µg/hour. It is available in a variety of formulations: Subutex, Suboxone (buprenorphine HCl and naloxone HCl; typically used for opioid addiction), Temgesic (sublingual tablets for moderate to severe pain), Buprenex (solutions for injection often used for acute pain in primary-care settings), Norspan and Butrans (transdermal preparations used for chronic pain). (Wikipedia)
1beta-hydroxy-tirucalla-3,23-dione-7,24-diene-1(2->3)abeo-1-carboxamide|aphanamgrandin F
C30H45NO4 (483.33484100000004)
Taurolithocholic acid
C26H45NO5S (483.30182800000006)
D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids D013501 - Surface-Active Agents > D003902 - Detergents The bile acid taurine conjugate of lithocholic acid. KEIO_ID T072
Tauro 3a-OH-5b-cholanic acid
C26H45NO5S (483.30182800000006)
BA-134-150. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-134-120. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-134-90. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan. BA-134-60. In-source decay; 1 microL of the bile acid in MeOH solution was flow injected. Sampling interval was 1 Hz.; This record was created by the financial support of MEXT/JSPS KAKENHI Grant Number 17HP8021 (2017) to the MassBank database committee of the Mass Spectrometry Society of Japan.
2-((4R)-4-((5S,9S,10S,12R,13R,14S,17R)-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
C26H45NO5S (483.30182800000006)
2-((4R)-4-((3R,5R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
C26H45NO5S (483.30182800000006)
2-((4R)-4-((5S,9S,10S,12S,13R,14S,17R)-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
C26H45NO5S (483.30182800000006)
Lithocholyltaurine
C26H45NO5S (483.30182800000006)
D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids D013501 - Surface-Active Agents > D003902 - Detergents
Ile Pro Arg Val
C22H41N7O5 (483.31690160000005)
Ile Pro Val Arg
C22H41N7O5 (483.31690160000005)
Ile Arg Pro Val
C22H41N7O5 (483.31690160000005)
Ile Arg Val Pro
C22H41N7O5 (483.31690160000005)
Ile Val Pro Arg
C22H41N7O5 (483.31690160000005)
Ile Val Arg Pro
C22H41N7O5 (483.31690160000005)
Leu Pro Arg Val
C22H41N7O5 (483.31690160000005)
Leu Pro Val Arg
C22H41N7O5 (483.31690160000005)
Leu Arg Pro Val
C22H41N7O5 (483.31690160000005)
Leu Arg Val Pro
C22H41N7O5 (483.31690160000005)
Leu Val Pro Arg
C22H41N7O5 (483.31690160000005)
Leu Val Arg Pro
C22H41N7O5 (483.31690160000005)
Pro Ile Arg Val
C22H41N7O5 (483.31690160000005)
Pro Ile Val Arg
C22H41N7O5 (483.31690160000005)
Pro Leu Arg Val
C22H41N7O5 (483.31690160000005)
Pro Leu Val Arg
C22H41N7O5 (483.31690160000005)
Pro Arg Ile Val
C22H41N7O5 (483.31690160000005)
Pro Arg Leu Val
C22H41N7O5 (483.31690160000005)
Pro Arg Val Ile
C22H41N7O5 (483.31690160000005)
Pro Arg Val Leu
C22H41N7O5 (483.31690160000005)
Pro Val Ile Arg
C22H41N7O5 (483.31690160000005)
Pro Val Leu Arg
C22H41N7O5 (483.31690160000005)
Pro Val Arg Ile
C22H41N7O5 (483.31690160000005)
Pro Val Arg Leu
C22H41N7O5 (483.31690160000005)
Arg Ile Pro Val
C22H41N7O5 (483.31690160000005)
Arg Ile Val Pro
C22H41N7O5 (483.31690160000005)
Arg Leu Pro Val
C22H41N7O5 (483.31690160000005)
Arg Leu Val Pro
C22H41N7O5 (483.31690160000005)
Arg Pro Ile Val
C22H41N7O5 (483.31690160000005)
Arg Pro Leu Val
C22H41N7O5 (483.31690160000005)
Arg Pro Val Ile
C22H41N7O5 (483.31690160000005)
Arg Pro Val Leu
C22H41N7O5 (483.31690160000005)
Arg Val Ile Pro
C22H41N7O5 (483.31690160000005)
Arg Val Leu Pro
C22H41N7O5 (483.31690160000005)
Arg Val Pro Ile
C22H41N7O5 (483.31690160000005)
Arg Val Pro Leu
C22H41N7O5 (483.31690160000005)
Val Ile Pro Arg
C22H41N7O5 (483.31690160000005)
Val Ile Arg Pro
C22H41N7O5 (483.31690160000005)
Val Leu Pro Arg
C22H41N7O5 (483.31690160000005)
Val Leu Arg Pro
C22H41N7O5 (483.31690160000005)
Val Pro Ile Arg
C22H41N7O5 (483.31690160000005)
Val Pro Leu Arg
C22H41N7O5 (483.31690160000005)
Val Pro Arg Ile
C22H41N7O5 (483.31690160000005)
Val Pro Arg Leu
C22H41N7O5 (483.31690160000005)
Val Arg Ile Pro
C22H41N7O5 (483.31690160000005)
Val Arg Leu Pro
C22H41N7O5 (483.31690160000005)
Val Arg Pro Ile
C22H41N7O5 (483.31690160000005)
Val Arg Pro Leu
C22H41N7O5 (483.31690160000005)
2-(Hydroxyimino)-3-oxo-olean-12-en-28-oic acid
C30H45NO4 (483.33484100000004)
bis(2-hydroxyethyl)methyl(octadecyl)ammonium methyl sulphate
C24H53NO6S (483.35933980000004)
Glycocholic acid (hydrate)
Otilonium
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators D005765 - Gastrointestinal Agents
2-((4R)-4-((5S,9S,10S,12S,13R,14S,17R)-12-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonic acid
C26H45NO5S (483.30182800000006)
(4Z,7Z,10Z,13Z,16Z,19Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]docosa-4,7,10,13,16,19-hexaenamide
(3Z,6Z,9Z,12Z,15Z)-N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]octadeca-3,6,9,12,15-pentaenamide
(4Z,7Z,10Z,13Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]hexadeca-4,7,10,13-tetraenamide
2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxydecane-1-sulfonic acid
C26H45NO5S (483.30182800000006)
(E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxydec-4-ene-1-sulfonic acid
C26H45NO5S (483.30182800000006)
2-[4-[(3R,5R,8R,9S,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid
C26H45NO5S (483.30182800000006)
2-[[(4R)-4-[(5S,8R,9S,10S,12R,13R,14S,17R)-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic acid
C26H45NO5S (483.30182800000006)
Oxolucidine B
An organonitrogen heterocyclic compound that is lucidine B in which the hydrogen at the 4a position of the dodecahydrobenzo[5,6]cyclohepta[1,2-b]pyridinyl moiety is substituted by a hydroxy group.
hainanate A
A steroid acid anion that is the conjugate base of hainanic acid A resulting from the deprotonation of the carboxy group; major species at pH 7.3.
(2r,4as,6as,6br,8ar,10z,12ar,12br,14br)-10-(methoxyimino)-2,4a,6a,6b,9,9,12a-heptamethyl-3,4,5,6,7,8,8a,11,12,12b,13,14b-dodecahydro-1h-picene-2-carboxylic acid
5-(6-hydroxy-3,6,7-trimethyloct-1-en-3-yl)-10-isopropyl-13-(methoxymethyl)-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol
C29H45N3O3 (483.34607400000004)
3-methyl-2-({3-methyl-2-[1-(2-methyldecanoyl)pyrrolidine-2-carbonyloxy]butanoyl}oxy)butanoic acid
9,18,20,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol
C29H41NO5 (483.29845760000006)
methyl (2z,6s)-6-[(1s,3as,5ar,7e,9ar,9br,11as)-7-(hydroxyimino)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoate
methyl (3s,3'r,3'as,6's,6as,6bs,7'ar,9r,11as,11br)-3-hydroxy-3',6',10,11b-tetramethyl-11-oxo-1,2,3,3',3'a,4,5',6,6',6a,6b,7,7',7'a,8,11a-hexadecahydrospiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-4'-carboxylate
C29H41NO5 (483.29845760000006)
3-[(4e,6e,8s,11z)-13-[(2s)-5-hydroxy-4-methyl-3-oxo-2h-furan-2-yl]-4,8,12-trimethyltrideca-4,6,11-trien-1-yl]-1-(3-methylbutyl)-5h-pyrrol-2-one
C30H45NO4 (483.33484100000004)
3-[13-(3-hydroxy-4-methyl-5-oxo-2h-furan-2-yl)-4,8,12-trimethyltrideca-4,6,11-trien-1-yl]-1-(3-methylbutyl)-5h-pyrrol-2-one
C30H45NO4 (483.33484100000004)
(9s,10r,11r,12s,14r,15e,26s)-9,19,21,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol
C29H41NO5 (483.29845760000006)
(10s,13s)-5-[(3r)-6-hydroxy-3,6,7-trimethyloct-1-en-3-yl]-10-isopropyl-13-(methoxymethyl)-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol
C29H45N3O3 (483.34607400000004)
(2s,4's,6r,6'r,8's,9'r)-6-{[(4ar,5r,7s,8as)-1-acetyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-6',12'-dimethyl-12'-azaspiro[piperidine-2,2'-tricyclo[6.2.2.0⁴,⁹]dodecan]-3-one
1-[5-({2-hydroxy-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl}methyl)-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
(9s,10r,11r,12s,14r,15z,26s)-9,19,21,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol
C29H41NO5 (483.29845760000006)
(3e,5e,7e,15e,17e,19e,21e,23z)-9,18,20,26-tetramethyl-1-azacyclohexacosa-1,3,5,7,15,17,19,21,23-nonaene-2,10,11,12,14-pentol
C29H41NO5 (483.29845760000006)
methyl (3s,3's,3'as,6's,6as,6br,7'as,9r,11ar,11br)-3-hydroxy-3',6',10,11b-tetramethyl-11-oxo-1,2,3,3',3'a,4,5',6,6',6a,6b,7,7',7'a,8,11a-hexadecahydrospiro[cyclohexa[a]fluorene-9,2'-furo[3,2-b]pyridine]-4'-carboxylate
C29H41NO5 (483.29845760000006)
1-[(4ar,5r,7s,8as)-5-{[(1r,2s,5r,9s,11r,13s,17r)-2-hydroxy-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
1-[(4ar,5r,7s,8as)-5-{[(1s,2s,5r,9s,11r,13s,17r)-2-hydroxy-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadec-6-en-5-yl]methyl}-7-methyl-octahydro-2h-quinolin-1-yl]ethanone
6-[(1-acetyl-7-methyl-octahydro-2h-quinolin-5-yl)methyl]-6',12'-dimethyl-12'-azaspiro[piperidine-2,2'-tricyclo[6.2.2.0⁴,⁹]dodecan]-3-one
(10s,13s)-5-[(3r,6r)-6-hydroxy-3,6,7-trimethyloct-1-en-3-yl]-10-isopropyl-13-(methoxymethyl)-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol
C29H45N3O3 (483.34607400000004)